Despite intensive multimodal therapy, the survival rate for high risk neuroblastoma (HR-NB)
remains< 50%. Most cases initially respond to treatment but almost half will subsequently …

Dinutuximab, which is a monoclonal antibody targeting GD2 expressed in neuroblasts,
improves survival when included in the therapy regimen. This article reviews the importance …

High-risk neuroblastoma (NB) accounts for 15% of all pediatric cancer deaths. Refractory
disease for high-risk NB patients is attributed to chemotherapy resistance and …

Neuroblastoma, a paediatric malignancy of the peripheral nervous system, displays a wide
range of clinical outcomes, including regression to fatality despite extensive treatment …

Magnetic resonance–guided high-intensity focused ultrasound (MRgHIFU) is a novel
treatment for neuroblastoma using ultrasound-induced thermal ablation with real-time MR …

Carbohydrates are a major class of biomolecules in living organisms that are necessary for
several important biological processes, such as cell–cell adhesion, cell signaling, protein …

High-risk neuroblastoma (NB) accounts for 15% of all pediatric cancer deaths. Refractory
disease for high-risk NB patients is attributed to chemotherapy resistance and …

Neuroblastoma (NB) is the commonest extra-cranial malignant solid tumour of childhood
and one of the most difficult to cure. Long term survival of high-risk NB (HR-NB) currently …

Neuroblastoma is the third most common pediatric cancer. Dinutuximab is a recently
approved monoclonal antibody targeting GD2, a ganglioside ubiquitously present on …